1. Signaling Pathways
  2. Immunology/Inflammation
  3. CX3CR1

CX3CR1

CX3C chemokine receptor1; GPR13; fractalkine receptor

CX3C chemokine receptor1 (CX3CR1), also known as the fractalkine receptor or GPR13, is the specific receptor to the CX3CL1. As the name suggests, CX3CR1 binds the chemokine CX3CL1 (also called fractalkine (in humans) or neurotactin (in mouse) ). CX3CL1 is a member of the CX3C family and that has been detected on activated endothelial cells, smooth muscle cells (SMCs), macrophages and platelets. CX3CL1 is the only neuronal chemokine in the body with pro-inflammatory, anti-inflammatory and neuroprotective effects, and is involved in the development of numerous inflammatory pathologies including atherosclerosis, rheumatoid arthritis, or graft rejection.

CX3CR1 Related Products (4):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-13848
    AZD8797
    98.73%
    AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively.
    AZD8797
  • HY-123918
    JMS-17-2
    99.90%
    JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells.
    JMS-17-2
  • HY-107456
    E6130
    ≥98.0%
    E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
    E6130
  • HY-123918A
    JMS-17-2 hydrochloride
    JMS-17-2 hydrochloride is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 hydrochloride impairs metastatic seeding and colonization of breast cancer cells.
    JMS-17-2 hydrochloride